How does RankPeptide rank peptides?

RankPeptide uses an auditable, transparent scoring formula based on five evidence dimensions: (1) Number of published clinical studies — compounds with more peer-reviewed publications score higher, weighted toward human trials over animal studies. (2) Recency of research — peptides with active, ongoing clinical investigation receive a recency bonus, because newer data better reflects the current scientific understanding. (3) Safety profile data — compounds with well-documented safety profiles, including adverse event reporting and toxicology data, score higher than those with limited safety information. (4) Clinical impact evidence — this measures the magnitude of observed effects in controlled trials, such as percentage weight loss in GLP-1 studies or wound healing rates in BPC-157 animal models. (5) Research volume — the total breadth of scientific inquiry, including systematic reviews, meta-analyses, and conference presentations. Every score on RankPeptide links directly to PubMed IDs (PMIDs) so you can verify the underlying research yourself. We do not accept payment for rankings, and compounds without affiliate partnerships are scored identically to those with them. The methodology page explains each weighting factor in detail.

What are evidence tiers for peptides?

RankPeptide classifies all 24+ peptides in our database into four evidence tiers, each representing a distinct level of scientific validation. Tier 1 (FDA-Approved) includes compounds that have completed Phase III clinical trials and received regulatory approval — examples include semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and PT-141 (Vyleesi). These have the strongest evidence base with thousands of human participants studied. Tier 2 (Clinical Data) covers peptides with published human clinical trials in peer-reviewed journals but without full FDA approval — examples include BPC-157, CJC-1295, Ipamorelin, GHK-Cu, Selank, and Semax. These have meaningful human evidence but smaller sample sizes. Tier 3 (Preclinical) includes peptides studied in animal models and in-vitro experiments with promising but unconfirmed human relevance — examples include TB-500, Epithalon, MOTS-c, AOD-9604, and LL-37. Tier 4 (Early Research) covers compounds with very limited published data, primarily theoretical or mechanistic — Dihexa is the primary example. Each tier is color-coded throughout the RankPeptide app (green for Tier 1, blue for Tier 2, amber for Tier 3, red for Tier 4) so you can instantly assess evidence strength.

How do I choose the right peptide for my goals?

RankPeptide offers a free personalized Find Peptide quiz that matches you to research peptides based on your specific health goals. The process works in three steps: First, you select your biological sex (male or female) — this matters because peptide responses differ between sexes, particularly for hormonal compounds like growth hormone secretagogues and GLP-1 agonists. Second, you enter your date of birth, since age affects peptide metabolism and research relevance. Third, you choose your primary health goals from categories including recovery and healing, fat loss and metabolic health, anti-aging, cognitive enhancement, muscle growth, joint health, gut health, sleep improvement, and immune support. The quiz then generates a personalized ranking of peptides suited to your profile, ordered by research evidence strength rather than popularity or marketing hype. Each recommendation includes the evidence tier, key clinical studies, dosage protocols used in research, and safety considerations. You can also use the Search and Rankings pages to explore peptides manually, filter by category, and compare effectiveness scores across specific goals. The Effectiveness Rankings page shows confidence-weighted comparisons so you can distinguish between peptides with strong clinical backing versus those with only anecdotal support.

Are peptide supplier rankings on RankPeptide paid placements?

No — RankPeptide supplier trust scores are based entirely on objective, verifiable criteria and are never influenced by affiliate partnerships or payment. The trust score formula evaluates four dimensions: (1) Third-party COA (Certificate of Analysis) verification — suppliers must provide recent COAs from independent laboratories showing HPLC purity testing results, typically requiring 98%+ purity for a top score. (2) Shipping reliability — based on tracked delivery times, packaging quality (cold chain for temperature-sensitive peptides), and customer-reported delivery success rates. (3) Peptide range — suppliers offering a broader selection of research-grade peptides with consistent quality across their catalog score higher. (4) Community trust — aggregated from verified customer reviews, forum reputation (Reddit, peptide communities), and longevity in the market. Some suppliers on RankPeptide have affiliate partnerships, and this is always clearly disclosed with a small badge on their listing. However, suppliers without any affiliate relationship are included and ranked using the exact same criteria. For example, if a non-affiliate supplier has better COA verification than an affiliate partner, the non-affiliate will rank higher. Our editorial independence policy is published on the site, and we encourage users to verify COAs independently using the guide in our blog.

What is the difference between BPC-157 and TB-500?

BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) are both popular research peptides in the recovery and healing category, but they differ significantly in origin, mechanism, evidence level, and research applications. BPC-157 is a pentadecapeptide (15 amino acids) derived from human gastric juice. It is classified as Tier 2 on RankPeptide due to its extensive preclinical evidence and emerging human clinical data. Its primary mechanisms include promoting angiogenesis (new blood vessel formation), modulating the nitric oxide system, upregulating growth hormone receptors, and interacting with the dopaminergic system. Research protocols typically use 200-500 mcg administered 1-2 times daily via subcutaneous injection or orally for gut-specific effects, over 4-8 week cycles. TB-500 is a synthetic version of the naturally occurring 43-amino-acid peptide Thymosin Beta-4. It is classified as Tier 3 (Preclinical) with primarily animal study data. TB-500 works by upregulating actin (a key protein for cell migration and proliferation), reducing inflammation through cytokine modulation, and promoting tissue regeneration. Research protocols typically use 2-5 mg administered 2 times weekly via subcutaneous injection over 4-8 weeks. Many researchers study BPC-157 and TB-500 together (the 'Wolverine Stack') because they appear to work through complementary mechanisms — BPC-157 targeting vasculature and gut tissue, TB-500 targeting broader systemic tissue repair. RankPeptide's detailed comparison guide covers the full evidence base for both compounds.

MK-677 vs HGH in 2026: Ibutamoren Compared to Growth Hormone Therapy

MK-677 (ibutamoren) and exogenous human growth hormone (HGH) are two of the most commonly compared compounds in the growth hormone optimization space. Both elevate GH and IGF-1 levels, but they do so through fundamentally different mechanisms — and those differences carry significant implications for efficacy, safety, cost, and practical use. This evidence-based comparison breaks down everything researchers and informed consumers need to know about MK-677 vs HGH in 2026.

How MK-677 and HGH Work: Key Mechanisms

MK-677 (Ibutamoren) is an orally active growth hormone secretagogue that mimics ghrelin, binding to the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary gland. Rather than introducing external growth hormone, MK-677 stimulates your body's own pituitary gland to produce and release GH in natural pulsatile patterns. This is a critical distinction: MK-677 works with the hypothalamic-pituitary axis, not around it.

Exogenous HGH (recombinant human growth hormone, e.g., somatropin) is a direct injection of synthetic growth hormone identical to the 191-amino-acid protein produced by the pituitary. It bypasses the body's regulatory feedback mechanisms entirely, delivering a bolus of GH regardless of the body's current signaling state.

Clinical Evidence: What the Research Shows

MK-677 Clinical Data

MK-677 has been evaluated in multiple human clinical trials spanning different populations. A landmark 1998 study published in the Journal of Clinical Endocrinology & Metabolism found that two months of daily oral MK-677 (25 mg) in healthy obese subjects increased GH secretion, fat-free mass, and energy expenditure without significantly altering fat mass or blood glucose at that timeframe (<a href="https://pubmed.ncbi.nlm.nih.gov/9467534/" target="_blank" rel="noopener noreferrer">PMID: 9467534</a>).

A 2008 randomized, double-blind, placebo-controlled trial in Annals of Internal Medicine studied MK-677 over 12 months in 65 healthy older adults (60-81 years). Daily MK-677 administration increased GH and IGF-1 levels to those of younger adults, with notable increases in fat-free mass and some improvement in functional measures. However, the study also documented increases in fasting glucose and insulin resistance in some participants (<a href="https://pubmed.ncbi.nlm.nih.gov/18981485/" target="_blank" rel="noopener noreferrer">PMID: 18981485</a>).

Another key study demonstrated MK-677's anti-catabolic properties. Published in the Annals of Internal Medicine in 1997, researchers showed that MK-677 reversed diet-induced nitrogen wasting (protein catabolism) in healthy volunteers placed on caloric restriction, suggesting potential utility in muscle-wasting conditions (<a href="https://pubmed.ncbi.nlm.nih.gov/9349662/" target="_blank" rel="noopener noreferrer">PMID: 9349662</a>).

Exogenous HGH Clinical Data

Exogenous HGH has decades of clinical data as an FDA-approved therapy for growth hormone deficiency. The foundational 1990 study by Rudman et al. in the New England Journal of Medicine demonstrated that six months of HGH therapy in men over 60 increased lean body mass by 8.8%, decreased fat mass by 14.4%, and increased skin thickness — sparking widespread interest in GH for anti-aging applications (<a href="https://pubmed.ncbi.nlm.nih.gov/2355952/" target="_blank" rel="noopener noreferrer">PMID: 2355952</a>).

A comprehensive 2007 systematic review in Annals of Internal Medicine analyzed 31 studies involving 220 participants receiving HGH and found consistent increases in lean body mass (average +2.0 kg) and reductions in fat mass (average -2.1 kg). However, it also documented high rates of side effects including soft tissue edema, joint pain, carpal tunnel syndrome, and increased diabetes risk (<a href="https://pubmed.ncbi.nlm.nih.gov/17284630/" target="_blank" rel="noopener noreferrer">PMID: 17284630</a>).

Head-to-Head Comparison: MK-677 vs HGH

While no large-scale trial has directly compared MK-677 to exogenous HGH in a head-to-head format, the available evidence allows us to draw meaningful comparisons across several dimensions:

GH and IGF-1 Elevation

HGH produces supraphysiological GH spikes immediately after injection, with dose-dependent IGF-1 increases. Levels can be precisely titrated by adjusting the dose. MK-677 elevates GH and IGF-1 to the high end of the physiological range — typically restoring levels to those of a young adult — but does not push levels as far beyond the normal range as high-dose exogenous HGH. For researchers focused on restoring age-related GH decline, MK-677's physiological pulsatile pattern may actually be preferable.

Administration and Convenience

MK-677 is taken orally — a single capsule or liquid dose daily. This is a significant practical advantage. HGH requires daily subcutaneous injections, cold-chain storage, and reconstitution if using lyophilized powder. For long-term use, the convenience gap between an oral compound and daily injections is substantial.

Side Effect Profiles

MK-677's most commonly reported side effects include increased appetite (due to ghrelin receptor activation), water retention, mild lethargy, and — importantly — potential increases in fasting blood glucose and insulin resistance with prolonged use. The appetite stimulation can be significant and is the most frequently cited reason for discontinuation.

HGH side effects at therapeutic or supraphysiological doses include joint pain, carpal tunnel syndrome, edema, insulin resistance, and potential acceleration of existing neoplasms. Because exogenous HGH bypasses normal feedback mechanisms, the risk of pushing GH/IGF-1 to problematic levels is higher when dosing is not medically supervised.

Cost Comparison

MK-677 is available as a research compound at a fraction of the cost of pharmaceutical-grade HGH. A month's supply of MK-677 from a reputable research supplier typically costs $40-80. Pharmaceutical HGH (Genotropin, Norditropin, etc.) can cost $800-3,000+ per month without insurance, depending on the dose. Even generic somatropin remains significantly more expensive than MK-677.

Regulatory Status

HGH is FDA-approved for specific medical conditions (growth hormone deficiency, AIDS-related wasting, short bowel syndrome) and is available by prescription. Off-label use for anti-aging is common but exists in a regulatory gray area. MK-677 is not FDA-approved and is classified as an investigational drug. It is available as a research chemical but is prohibited in competitive sports by WADA.

Who Might Prefer MK-677 Over HGH?

Based on the available research, MK-677 may be better suited for individuals looking for a more moderate, physiological approach to GH optimization. Its oral bioavailability eliminates injection burden, and its mechanism of working through the body's own signaling pathways means the pituitary's feedback loops remain intact. It is also substantially more affordable, making it accessible for longer-term research protocols.

Exogenous HGH may be more appropriate when precise dose titration is required, when GH deficiency is clinically diagnosed, or when the goal is to achieve supraphysiological GH levels under medical supervision. Its decades of clinical data and FDA-approved status provide a stronger regulatory and safety evidence base.

Important Safety Considerations

Both MK-677 and exogenous HGH carry metabolic risks, particularly around insulin resistance and glucose homeostasis. Anyone considering either compound should monitor fasting glucose, HbA1c, and IGF-1 levels regularly. Neither should be used by individuals with active malignancies, as elevated IGF-1 may promote tumor growth. Medical supervision is strongly recommended for both compounds.

MK-677's long half-life (~24 hours) means effects are sustained but also means side effects persist throughout the dosing period. Some researchers employ cycling protocols (e.g., 8 weeks on, 4 weeks off) to manage appetite and insulin sensitivity effects, though this approach has not been formally studied.

Comparison Summary Table

Mechanism: MK-677 stimulates endogenous GH release via ghrelin receptor | HGH provides direct exogenous GH Administration: MK-677 is oral (daily) | HGH requires subcutaneous injection (daily) GH Pattern: MK-677 produces pulsatile, physiological release | HGH creates a bolus spike IGF-1 Increase: MK-677 is moderate (to high-normal range) | HGH is dose-dependent (can be supraphysiological) Key Side Effects: MK-677 causes increased appetite, water retention, glucose elevation | HGH causes joint pain, edema, carpal tunnel, glucose elevation Approximate Cost: MK-677 is $40-80/month | HGH is $800-3,000+/month FDA Status: MK-677 is investigational | HGH is approved for specific conditions Clinical Evidence: MK-677 has moderate (Phase II trials) | HGH has extensive (decades of data)

The Bottom Line

MK-677 and HGH both elevate growth hormone and IGF-1, but through fundamentally different pathways. MK-677 offers the advantages of oral dosing, physiological GH release patterns, preserved pituitary feedback, and dramatically lower cost. HGH offers precise dose control, extensive clinical data, and FDA-approved status for diagnosed deficiency states. The choice between them depends on the specific research goals, budget, risk tolerance, and whether medical supervision is available.

Want to explore how MK-677 compares to other growth hormone peptides like <a href="/app/detail/cjc1295">CJC-1295</a>, <a href="/app/detail/ipamorelin">Ipamorelin</a>, or <a href="/app/detail/sermorelin">Sermorelin</a>? Use the <a href="/app/rankings">RankPeptide comparison tool</a> to see side-by-side research data, safety profiles, and protocol details for every major peptide.

References

1. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369. <a href="https://pubmed.ncbi.nlm.nih.gov/9467534/" target="_blank" rel="noopener noreferrer">PMID: 9467534</a> 2. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. <a href="https://pubmed.ncbi.nlm.nih.gov/18981485/" target="_blank" rel="noopener noreferrer">PMID: 18981485</a> 3. Murphy MG, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-325. <a href="https://pubmed.ncbi.nlm.nih.gov/9467534/" target="_blank" rel="noopener noreferrer">PMID: 9349662</a> 4. Rudman D, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. <a href="https://pubmed.ncbi.nlm.nih.gov/2355952/" target="_blank" rel="noopener noreferrer">PMID: 2355952</a> 5. Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. <a href="https://pubmed.ncbi.nlm.nih.gov/17284630/" target="_blank" rel="noopener noreferrer">PMID: 17284630</a>